Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk FY25 Results | Contract Pharma

What are you searching for?

Sign in
Financial News

Novo Nordisk FY25 Results

Total GLP-1 sales were $24.0 billion, up 2%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Novo Nordisk

Novo Nordisk

FY Revenues: $48.7 billion +6%

FY Earnings: $16.1 billion +1%

Comments: Total GLP-1 sales for the full year 2025, which includes Ozempic, Victoza and Rybelsus, were $24.0 billion, up 2%. Ozempic sales were up 6% while Victoza sales were down 45% and Rybelsus sales were down 5%. Total insulin sales were $8.4 billion, down 4%. Obesity drug sales were up 26% to $12.97 billion and includes Wegovy and Saxenda. Rare disease sales totaled $3.1 billion, up 5%.

Sales growth was driven by both US Operations and International Operations. The volume growth of the global branded GLP-1 obesity market was 104%, where Novo Nordisk has a branded volume market share of 59.6%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics